NASDAQHealth CareMedical - DevicesSnapshot 2026-08-31
Reading PODD? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Broken: Primary pillar broken — Operating profit margin near 17.4% in 2025: TTM operating margin 16.9% vs 17.3% target; Q2 FY26 16.2% vs 16% trip.
Insulet grows revenue about 23% a year. Profit margin is near 17%. The company buys back shares to help shareholders. New product updates improve its insulin delivery system.
Product recalls and legal issues could hurt sales and reputation. Management changes add uncertainty. Guidance cuts show growth risks ahead.
The price is about 25% below our fair value near $215. Analysts expect 23% revenue growth. Our view aligns with this but sees risks from recent guidance cuts.
Breaks if: New major product recall or safety correction announced
Breaks if: Operating margin falls below 16% in FY25
Breaks if: YoY revenue growth falls below 22% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on revenue growth and margin stability. The current thesis state is intact, supported by strong recent financial performance despite some volatility in management execution.
The market appears to have priced in a neutral valuation, with PODD being seen as cheap compared to its peers. There is a slight expectations gap, suggesting that while the stock is not overly expensive, it is also not reflecting significant growth potential.
Fundamentals are likely to continue improving, as management has consistently raised revenue growth outlooks and maintained gross margins above 71%. However, there is an elevated risk due to potential guidance cuts and recent industry misses, which could impact performance.
The long-term thesis hinges on the ability of PODD to sustain its revenue growth and margin targets, as well as the performance of sector bellwethers like ABT, SYK, and MDT. Additionally, macroeconomic factors, such as job reports and recession fears, could significantly influence the stock's trajectory.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'favorable'.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Advances in Omnipod 5 product innovation and market expansion enhance growth potential. No new threats have emerged to weaken this view.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Repurchases drop below 1 million shares in next year
Insulet has expanded its share repurchase program to enhance shareholder value.
Overall, PODD shows solid fundamentals and a favorable sector backdrop, but it faces risks that could affect its performance. Not investment advice.
